Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Disease-Modifying Therapy of Pediatric Multiple Sclerosis.
Functional Homotopic Changes in Multiple Sclerosis with Resting-State Functional MR Imaging.
Novel Kv1.3 blockers for immunosuppression: W02012155199.
Emerging roles of system [Formula: see text] antiporter and its inhibition in CNS disorders.
Interferon beta assessment in non-Chinese and Chinese subjects: Pharmacokinetics and pharmacodynamic activity of an endogenous cytokine are not race dependent.
Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes.
Vitamin D and multiple sclerosis.
The role of Toll-like receptors in multiple sclerosis and possible targeting for therapeutic purposes.
Age of Onset as a Moderator of Cognitive Decline in Pediatric-Onset Multiple Sclerosis.
IL-17-induced MiR-873 attributes to the pathogenesis of experimental autoimmune encephalomyelitis by targeting A20 ubiquitin editing enzyme.
Gait variability in multiple sclerosis: a better falls predictor than EDSS in patients with low disability.
Endotoxin-induced systemic inflammation activates microglia: [(11)C]PBR28 positron emission tomography in nonhuman primates.
Cerebrospinal fluid myelin basic protein is frequently ordered but has little value: a test utilization study.
Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica.
Obtaining from Grape Pomace an Enzymatic Extract with Anti-inflammatory Properties.
A concise synthesis of Fingolimod: an orally available drug for treating multiple sclerosis.
Neuromyelitis optica spectrum disorder as a paraneoplastic manifestation of lung adenocarcinoma expressing aquaporin-4.
Is the use of the trivalent influenza vaccine against A (H1N1) pdm09 associated with an increased risk of post-vaccination acute disseminated encephalomyelitis?
Innovating openly: researchers and patients turn to crowdsourcing to collaborate on clinical trials, drug discovery, and more.
DQB1*06:02-Associated Pathogenic Anti-Myelin Autoimmunity in Multiple Sclerosis-Like Disease: Potential Function of DQB1*06:02 as a Disease-Predisposing Allele.
The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis.
Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers.
[Microglia in pathophysiology of neuroimmunological disorders].
Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE study.
Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis.
Pages
« first
‹ previous
…
349
350
351
352
353
354
355
356
357
…
next ›
last »